BioLife Sciences Inc. Seeks to Retain an Auditing and Consulting Services Firm
BioLife Sciences Inc. Seeks to Retain an Auditing and Consulting Services Firm
HENDERSON, NV, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences Inc. ("BioLife" or the "Company") (OTCPK: BLFE) announced that it is seeking to retain an auditing and consulting services firm with specific expertise with SEC filings, to assist with the pursuit of becoming fully reporting with sights set on up-listing to the Over-the-Counter Quotation Bureau ("OTCQB").
亨德森，內華達州，2022年11月3日(環球網)--通過NewMediaWire-BioLife Science Inc.(“BioLife”或“公司”)(場外交易市場代碼：BLFE)宣佈，它正在尋求保留一家在美國證券交易委員會備案文件方面具有特定專長的審計和諮詢服務公司，以幫助實現全面報告，並着眼於向場外報價局(“OTCQB”)上市。
Nika Jaksic, COO of Bio Life Sciences Inc., stated, "We are excited to announce this important next step, the assistance of experienced advisors will augment our team with the expertise necessary in achieving a successful transaction."
Bio Life Science Inc.首席運營官尼卡·雅克西奇表示：“我們很高興地宣佈這一重要的下一步行動，經驗豐富的顧問的協助將為我們的團隊提供成功交易所需的專業知識。”
The up-listing strategy is the latest endeavor for BioLife, which began 2022 with the acquisition of the orthomolecular medicine and natural health products company Health Box LLC and the launch of a life sciences division. The company's market focus areas include orthomoleculars, food and beverage – with a specific focus on superfoods, nutraceuticals and ethically sourced ingredients – material science and digital technology.
向上上市戰略是BioLife的最新努力，該公司始於2022年，收購了正分子藥物和天然保健品公司Health Box LLC，併成立了一個生命科學部門。該公司的市場重點領域包括鄰位分子、食品和飲料-特別側重於超級食品、營養食品和道德來源的配料-材料科學和數字技術。
About BioLife Sciences Inc.
關於生物生命科學公司
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences' core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
生物生命科學公司專門致力於將創新產品從實驗室或小規模生產轉移到更廣泛的市場採用。其核心業務是開發、許可和分銷抗菌產品和顛覆性技術。生物生命科學的核心組成部分戰略之一是開發、合作並協助創新公司將尖端技術商業化。
Disclaimer
免責
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
本新聞稿中的信息包括與管理層對未來事件、預期、計劃和前景的看法有關的某些信息和聲明，這些信息和聲明構成前瞻性聲明。這些陳述是基於受重大風險和不確定因素影響的假設。由於這些風險和不確定因素，以及各種因素的影響，實際結果、預期、成就或業績可能與這些前瞻性陳述中預期和表明的大不相同。本新聞稿中的前瞻性陳述包括但不限於該公司完成合格交易的能力。許多因素都可能導致實際結果與這些前瞻性陳述以及未來結果大不相同。儘管本公司相信前瞻性陳述中反映的預期是合理的，但它不能保證任何前瞻性陳述的預期將被證明是正確的。除非法律另有要求，否則本公司無意更新或修訂任何前瞻性陳述，以反映實際結果，無論是由於新信息、未來事件、假設的變化、影響此類前瞻性陳述的因素的變化或其他原因。
This is neither an offer nor a solicitation to sell securities, which may only be done once the Company's offering on Form 1-A has been qualified by the SEC and in those certain states where the Company seeks to offer its shares.
這既不是要約，也不是招攬出售證券，只有在本公司以1-A表格進行的發售已通過美國證券交易委員會以及在本公司尋求發售其股票的某些州的資格後，才能出售證券。
Contact Information:
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
聯繫方式：
郵箱：ir@biolifesciences.com
美國和加拿大：1(833)919-1037
譯文內容由第三人軟體翻譯。